Afuco™ Anti-IL13 ADCC Therapeutic Antibody (Tralokinumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IL13. Tralokinumab is a human monoclonal antibody which targets the cytokine interleukin 13, and is designed for the treatment of asthma and inflammatory diseases.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-218 |
| Pricing | Inquiry |
| Host | Human |
| Target | IL13 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | ELISA, FC, IP, FuncS, IF, Neut |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |